Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Invested Capital (2022 - 2025)

Beam Therapeutics (BEAM) has disclosed Return on Invested Capital for 3 consecutive years, with 0.46% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Invested Capital fell 27.0% to 0.46% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.46%, a 27.0% decrease, with the full-year FY2024 number at 0.48%, down 27.0% from a year prior.
  • Return on Invested Capital was 0.46% for Q1 2025 at Beam Therapeutics, up from 0.54% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.19% in Q1 2024 to a low of 0.54% in Q4 2024.
  • A 3-year average of 0.33% and a median of 0.22% in 2024 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 27bps in 2024; the steepest drop was -33bps in 2024.
  • Beam Therapeutics' Return on Invested Capital stood at 0.21% in 2023, then tumbled by -162bps to 0.54% in 2024, then grew by 15bps to 0.46% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Return on Invested Capital are 0.46% (Q1 2025), 0.54% (Q4 2024), and 0.22% (Q3 2024).